EPS for Collegium Pharmaceutical, Inc. (COLL) Expected At $-0.69; Invesco California Value Municipal Income Trust (VCV)’s Sentiment Is 1.64

April 17, 2018 - By Linda Rogers

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Logo

Invesco California Value Municipal Income Trust (VCV) investors sentiment increased to 1.64 in Q4 2017. It’s up 0.83, from 0.81 in 2017Q3. The ratio has improved, as 18 hedge funds started new or increased stock positions, while 11 sold and reduced their positions in Invesco California Value Municipal Income Trust. The hedge funds in our database now possess: 3.34 million shares, up from 3.12 million shares in 2017Q3. Also, the number of hedge funds holding Invesco California Value Municipal Income Trust in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 6 Increased: 8 New Position: 10.

Analysts expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report $-0.69 EPS on May, 9.They anticipate $0.10 EPS change or 12.66% from last quarter’s $-0.79 EPS. After having $-0.54 EPS previously, Collegium Pharmaceutical, Inc.’s analysts see 27.78% EPS growth. The stock increased 6.38% or $1.48 during the last trading session, reaching $24.68. About 309,462 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has risen 133.98% since April 17, 2017 and is uptrending. It has outperformed by 122.43% the S&P500.

The stock increased 0.09% or $0.01 during the last trading session, reaching $11.73. About 60,163 shares traded. Invesco California Value Municipal Income Trust (VCV) has declined 5.80% since April 17, 2017 and is downtrending. It has underperformed by 17.35% the S&P500.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $24,160 activity.

Jfs Wealth Advisors Llc holds 0.68% of its portfolio in Invesco California Value Municipal Income Trust for 220,630 shares. Shamrock Asset Management Llc owns 26,664 shares or 0.2% of their US portfolio. Moreover, Edge Wealth Management Llc has 0.16% invested in the company for 45,000 shares. The California-based Diligent Investors Llc has invested 0.09% in the stock. Syntal Capital Partners Llc, a Texas-based fund reported 23,119 shares.

Among 7 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical Inc had 18 analyst reports since February 19, 2016 according to SRatingsIntel. As per Tuesday, September 13, the company rating was initiated by Gabelli. The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Piper Jaffray on Thursday, December 14. Jefferies maintained the stock with “Buy” rating in Wednesday, August 16 report. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, January 23. The stock has “Outperform” rating by William Blair on Friday, February 19. The rating was maintained by Jefferies on Monday, June 12 with “Buy”. The firm has “Buy” rating given on Wednesday, October 18 by Jefferies. On Sunday, February 11 the stock rating was maintained by Jefferies with “Buy”. Janney Capital maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) on Friday, June 9 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, July 25.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $815.12 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: